Our cell therapy ambition
Join a team that, through collaboration with industry, academia, healthcare, and regulatory agencies, is shaping an ecosystem that drives access to cell therapies—connecting innovation and Commercial excellence to realize their full curative potential. To achieve this, we are building world-class cell therapy capabilities and advancing a diverse pipeline. We strive to be at the forefront of pioneering the latest technologies to eliminate the barriers standing between patients and cell therapies.
Our ambition is to realise the full curative potential of cell therapy across a wide range of diseases. We aim to empower the immune system to attack cancers, reset the underlying drivers of immune-mediated diseases, and deliver innovative solutions with the potential to improve the lives of people living with rare diseases.
Engineering Next-Generation Cell Therapies, from Discovery to Patient Access
Our leading gene-editing, lentivirus and biologics engineering capabilities enable us to engineer next-generation cell therapies that could overcome some of the challenges that exist today. We are pioneering innovative approaches to deliver the next wave of cell therapies that could more precisely and effectively target disease and be produced at scale.
Looking ahead, our pipeline is focused on delivering scalable, off-the-shelf solutions with the potential to transform how these therapies are positioned, accessed, and adopted globally. This evolution creates new opportunities to shape market access models, refine segmentation and targeting strategies, and leverage advanced insights and analytics to more effectively match therapies with the right patient populations.
Scaling manufacturing and clinical capabilities to bring cell therapies to more patients
We are building the infrastructure required to bring cell therapies to patients globally, continuing to scale our manufacturing and clinical capabilities while strengthening our commercial expertise to ensure these innovations reach patients effectively.
- Manufacturing cell therapies: Manufacturing cell therapies requires specialised capabilities, where the right technology, expertise, and infrastructure are critical to translating research into effective, scalable medicines. As we expand our global manufacturing footprint—now across eight locations—we are not only enabling clinical development, but also laying the foundation for future commercial supply, supporting broader patient access and market readiness.
- Clinical capabilities: We are enhancing our clinical capabilities through partnerships with renowned cell therapy treatment centres, including the Moffitt Cancer Center, to accelerate and expand access to cell therapy. Additionally, investigator-initiated trials of our investigational cell therapies in China have enabled rapid generation of proof of concept across oncology and immune-mediated diseases.
Enhancing our world-leading capabilities through external collaboration
Partnerships
- Moffitt Cancer Center: Our collaboration with the Moffitt Cancer Center aims to accelerate our oncology cell therapy pipeline.
- AbelZeta: Accelerating the development of our armoured CAR Ts for solid tumours in China.
- Cellectis: Harnessing our combined cell therapy expertise, capabilities and differentiated gene-editing technology to discover and develop novel allogeneic therapies.
- Medical research council: We are co-funding a postdoctoral fellowship scheme with the MRC to support research into key topics relating to cell therapy including patient safety, delivery in the human body and interactions with the immune system.
- Quell: Using proprietary Treg cell engineering technology to fix cells in a stable suppressive regulatory phenotype and potentially restore immune tolerance in the long term. Initially focusing on type 1 diabetes and inflammatory bowel disease.
Key Reasons to Join Our Cell Therapy Team
Cell therapy is a unique modality – by engineering living cells to precisely target disease we have the potential to transform patient outcomes across multiple therapeutic areas. At AstraZeneca, we are pioneering cell therapy at scale, investing in state-of-the-art platforms, building global capabilities and pushing the boundaries of science. Our aim is to ensure many more patients can benefit from cell therapy worldwide.
Craig Maxwell-
We’re building a diverse pipeline of cell therapies designed to overcome today’s toughest challenges — from persistence to scalability — and unlock new treatment possibilities across cancer, immune-mediated, and rare diseases.
Mark Cobbold
SVP, IO Discovery & Cell Therapy Oncology, AstraZeneca
Apply Now
- GP Sales Representative - South Adelaide R-243743 Macquarie Park, Australia
- Analista de CRM R-254958 Aeropuerto Internacional de la Ciudad de México, Mexico
- Associate Director, Clinical Operations Capabilities & Performance Excellence R-253449 Durham, North Carolina
- Director, Business Planning & Operations - Evinova R-254656 Gaithersburg, Maryland
- Senior Medical Affairs Lead - GYN R-254959 Gaithersburg, Maryland
- US Customs Operations Manager R-254960 Wilmington, Delaware
- Senior Manager Cell Therapy Hub R-254539 Wilmington, Delaware
- Global Study Manager - Haematology R-247782 Amsterdam, Netherlands
- Strategy Director (Consultant) - Clinical Development - Evinova R-254936 Cambridge, United Kingdom
- Financial Controller R-254942 San José, Costa Rica
